A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Humanized Monoclonal Antibody Specific to B- and T- Lymphocyte Attenuator, BTLA (JS004) Injection in Patients With Advanced Solid Tumors

An open-label, dose-escalation, phase I clinical study to evaluate the safety and tolerability of JS004 injection in the patients with advanced solid tumors who have failure in standard of care and are unable to tolerate standard of care and/or have no available standard of care. The study is divided into screening period, treatment period, and follow-up period.

1. Screening period: Subjects will be included in the screening period after signing the informed consent form (ICF). The screening period is up to 28 days, subjects will enter the study treatment period if they meet all the inclusion criteria and none of exclusion criterion.
2. Treatment period: Subjects will be allocated to the designated dose group to receive corresponding treatment in accordance with the progress of study. Subjects in dose escalation phase will receive DLT observation at first, and upon completion of DLT observation, the subjects will continue their administration at the original dose if they are tolerated as judged by investigator, until progression of disease, intolerable toxicity or other reasons specified in the protocol. Subjects in the dose extension phase receive appropriate study treatment until disease progression, intolerance of toxicity, or other causes specified in the protocol occur. Response evaluation criteria in solid tumors (RECIST v1.1) will be used for efficacy evaluation every 9 weeks (±7 days) in the first year and every 12 weeks (±7 days) in the 2nd year and thereafter.
3. Follow-up period: A safety follow-up visit is required 30 days (±7 days) after the last dose of study drug or before the initiation of new antitumor therapy. If the new antitumor therapy has not been initiated, additional safety follow-up should be completed 90 days (±7 days) after the last dose as far as possible.

Study Overview

• Status: Recruiting
• Conditions: Melanoma; Urothelial Carcinoma; Renal Carcinoma
• Intervention / Treatment: Biological: JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection

• Study Type: Interventional
• Enrollment (Anticipated): 156
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Liang Gao; Phone Number: 13263288215; Email: liang_gao@junshipharma.com
• Study Contact Backup: Name: Ling Xiao; Phone Number: 13408654655; Email: ling_xiao@junshipharma.com

Study Locations

• China
  • Beijing, China
    • Recruiting
    • Beijing Cancer Hospital
    • Contact: Jun Guo
  • Shanghai, China
    • Not yet recruiting
    • Fudan University Shanghai Cancer Center
    • Contact: Zhiguo Luo
  • Wuhan, China
    • Not yet recruiting
    • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
  • Fujian
    • Fuzhou, Fujian, China
      • Not yet recruiting
      • Fujian Provincial Cancer Hospital
      • Contact: Yu Chen
  • Heilongjiang
    • Harbin, Heilongjiang, China
      • Not yet recruiting
      • Tumor Hospital affiliated to Harbin Medical University
      • Contact: Jin Wu
  • Hunan
    • Changsha, Hunan, China
      • Not yet recruiting
      • Hunan Cancer hospital
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Not yet recruiting
      • Nanjing Drum Tower Hospital
      • Contact: Zhengyun Zou
  • Jilin
    • Changchun, Jilin, China
      • Not yet recruiting
      • First Hospital of Jilin University
      • Contact: Di Wu
  • Sichuan
    • Chengdu, Sichuan, China
      • Not yet recruiting
      • West China Hospital of Sichuan University
      • Contact: Jiyan Liu
  • Zhejiang
    • Hangzhou, Zhejiang, China
      • Not yet recruiting
      • Zhejiang Cancer Hospital
      • Contact: Yumei Fang
    • Hangzhou, Zhejiang, China
      • Not yet recruiting
      • Run Run Shaw Hospital affiliated to Zhejiang University Medical College

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Only the patients meeting the following criteria are eligible to participate in the study:

1. Voluntarily signed written informed consent form;
2. Age ≥18 and ≤70 years at the time of signing informed consent form, male or female;
3. Life expectancy ≥ 3 months;
4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;
5. Patients with histologically or cytologically confirmed advanced solid tumors: patients with advanced solid tumors who have failure in standard of care, cannot tolerate standard of care, refuse and/or have no standard of care (melanoma, renal carcinoma and urothelial carcinoma);
6. At least one measurable lesion as target lesion (RECIST v1.1);
7. Agree to provide tumor tissue specimen ( fresh biopsied sample before treatment should be provided as far as possible, the archived sample within two years is acceptable for the patients who cannot provide fresh biopsied sample before treatment);
8. Adequate organ function as indicated by the laboratory results during the screening period;
9. Use of effective contraceptive methods during the study for male subjects of reproduction ability or female subjects of childbearing potential, and continuation of contraception for 6 months after the end of treatment;
10. Good compliance, cooperation with follow-up.

Exclusion Criteria

Patients will be excluded from the study when they have any of the following conditions:

1. History of malignant tumors other than the disease investigated in the past 5 years, however, except for the malignant tumors that can be expected to be cured after treatment;
2. Having received systematic antitumor therapy, or local antitumor therapy, or treatment with clinically investigational medication or device within 4 weeks prior to the first dose of study drug;
3. Having received immunotherapy within 4 weeks prior to first dose of study drug;
4. Previously treated with anti-BTLA or anti-HVEM antibody;
5. Adverse reaction induced by previous therapy having not recovered to CTCAE (version 5.0) grade 1 or better;
6. Having previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
7. Having central nervous system metastases and/or cancerous meningitis;
8. Having or suspected to have active autoimmune disease;
9. Having hepatitis and liver cirrhosis;
10. Massive hydrothorax or ascites with clinical symptoms or requiring symptomatic treatment;
11. Having severe cerebro- and cardiovascular diseases;
12. Having pulmonary disease;
13. Having active infection requiring systemic treatment;
14. Positive result for human immunodeficiency virus (HIV) antibody;
15. Active hepatitis B or C;
16. Known active tuberculosis (TB);
17. Use of systemic corticosteroids 14 days prior to the first dose of study drug;
18. Use of broad-spectrum antibiotics that may affect the change of intestinal flora within 14 days prior to the first dose of study drug;
19. Vaccination of live vaccine within 4 weeks prior to the first dose of study drug;
20. Having received major surgery within 4 weeks prior to the first dose of study drug;
21. History of anti-psychotics abuse and unable to abstain, or with a history of mental disorder;
22. Pregnant or breast-feeding women;
23. Known allergy to JS004 and its components;
24. Other severe, acute or chronic medical conditions or mental diseases or laboratory abnormalities possibly increasing relevant risks in participation in the study or possibly interfering with the interpretation of study results as judged by investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Dose escalation and extension group; JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;; JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;; JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;; JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined.

Biological: JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection; Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the safety and tolerability of JS004 injection alone and in combination with Toripalimab in patients with advanced solid tumors.	Including incidence of dose limiting toxicity (DLT); incidence and severity of adverse event (AE), serious adverse event (SAE) and immune related adverse event (irAE); laboratory results with clinical significance and other tests with abnormal results.	2 years
Determine the maximum tolerated dose (MTD)/recommended extended dose (RDE) of JS004 injection monotherapy and combination with Toripalimab in patients with advanced solid tumors.	The maximum tolerated dose (MTD) is defined as the maximum dose at which <1/3 subjects experience any DLTs and at least 6 evaluable subjects are required at each dose level.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To preliminarily evaluate the efficacy of JS004 injection as a single drug and combined with Toripalimab.	Objective response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS) in accordance with RECIST 1.1 and overall survival (OS).	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Drug concentration in individual subject at different time points after administration.	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Peak concentration (Cmax)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Time to peak (Tmax)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Area under the serum concentration-time curve (AUC0-t and AUC0-∞)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Clearance (CL)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Volume of distribution under steady state (Vss)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Mean retention time (MRT)	2 years
To evaluate the pharmacokinetic profile of JS004 Injection as a single drug and combined with Toripalimab.	Elimination half-life (t1/2)	2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To exploratively evaluate the antitumor activity of JS004 injection as a single drug and combined with Toripalimab using iRECIST (2017).	Objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and progression-free survival (PFS) evaluated in accordance with iRECIST(2017).	2 years
To explore the pharmacodynamic profile of JS004 injection.	Pharmacodynamic variables related with targets: lymphocyte subpopulation, receptor occupancy.	2 years
To explore the correlation of relevant biomarkers with clinical efficacy.	Tumor tissue related biomarker: including but not limited to HVEM and PD-L1; density of CD8 positive tumor infiltrating immune cells; tumor tissue whole exon sequencing (WES); Peripheral blood related biomarker: cytokine; surface receptor on immune cell (including PD-1，HVEM, CTLA-4, CD112R, TIM-3, ICOS, CX3CR1, CD183, CD103).	2 years

Collaborators and Investigators

• Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 12, 2021
• Primary Completion (Anticipated): February 29, 2024
• Study Completion (Anticipated): August 31, 2024

Study Registration Dates

• First Submitted: January 17, 2021
• First Submitted That Met QC Criteria: February 24, 2021
• First Posted (Actual): February 26, 2021

Study Record Updates

• Last Update Posted (Actual): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 23, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Carcinoma, Renal Cell; Carcinoma; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Antibodies, Monoclonal
• Other Study ID Numbers: HMO-JS004-I-CT01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No